Both have already shown promising results in clinical trials of MASLD patients, suggesting a crucial role for PPAR interplay with epigenetic control mechanisms in the development of MASLD (Remely et al., 2017; Boubia et al., 2018; Sumida and Yoneda, 2018). The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.